Terns Pharmaceuticals to Present at 40th Annual J.P. Morgan Health Care Conference
04 January 2022 - 8:05AM
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq:
TERN), a clinical-stage biopharmaceutical company developing a
portfolio of small-molecule single-agent and combination therapy
candidates to address serious diseases such as non-alcoholic
steatohepatitis (NASH), today announced that the Company’s
management team will present at the following investor conferences
in January:
40th Annual J.P. Morgan Health Care
Conference
- Date: January 13, 2022
- Time: 11:15 a.m. ET
H.C. Wainwright BioConnect 2022 Virtual
Conference
- Date: January 10, 2022
- Time: 7:00 a.m. ET
A live audio webcast of each presentation will be available on
the investor relations page of Terns’ website at
http://ir.ternspharma.com. A replay of the webcast will be archived
on Terns’ website for 30 days following the presentation.
About Terns PharmaceuticalsTerns
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
developing a portfolio of small-molecule single-agent and
combination therapy candidates to address serious diseases such as
non-alcoholic steatohepatitis, or NASH. Terns’ pipeline includes
three clinical stage development programs including an FXR agonist,
a VAP-1 inhibitor and a THR-β agonist, and a preclinical
small-molecule GLP-1 receptor agonist program. For more
information, please visit: www.ternspharma.com.
Contacts for Terns
InvestorsJustin Nginvestors@ternspharma.com
MediaJenna UrbanBerry & Company Public
Relationsmedia@ternspharma.com
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Apr 2024 to May 2024
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From May 2023 to May 2024